AGA Medical’s Pipeline Diversifies Into Vascular Space
This article was originally published in The Gray Sheet
Executive Summary
AGA Medical, a maker of minimally invasive devices to treat heart defects, is expanding its product portfolio further into the vascular space
You may also be interested in...
AGA Medical expands Amplatzer line
Firm launches Amplatzer Muscular VSD Occluder for closure of complex ventricular septal defects following PMA approval Sept. 7. The device, which is placed via a transcatheter procedure in patients at high risk for surgical closure, is the latest addition to AGA's Amplatzer line. Also available in the United States are the Amplatzer septal occluder for atrial septal defects, and the Amplatzer duct occluder for closure of patent ductus arteriosus defects. The firm also offers vascular plugs ("1The Gray Sheet" Sept. 3, 2007, p. 11)
AGA Medical expands Amplatzer line
Firm launches Amplatzer Muscular VSD Occluder for closure of complex ventricular septal defects following PMA approval Sept. 7. The device, which is placed via a transcatheter procedure in patients at high risk for surgical closure, is the latest addition to AGA's Amplatzer line. Also available in the United States are the Amplatzer septal occluder for atrial septal defects, and the Amplatzer duct occluder for closure of patent ductus arteriosus defects. The firm also offers vascular plugs ("1The Gray Sheet" Sept. 3, 2007, p. 11)
Devices In Drug Land: Med-Tech Firms Try To Break Into Pharma Territory
Medical device companies are targeting everything from headaches to psychiatric disorders and from digestive diseases to cardiac conditions in an effort to win over just a portion of these and other multibillion-dollar drug-dominated markets